Stock Trades Lower -- Simcere Pharmaceutical Group (SCR) said its revenues and profits were sharply higher in the second quarter, when compared to results a year ago. The company saw its sales rise 51% to 355 million RMB ($46.6 million), while net earnings advanced 67% to 49.7 million RMB ($10.9 million). Simcere manufactures and markets first-to-market generics in the Chinese market (see story). More details...